The DOI matches its Crossref record; 295 of the 295 references it cites were found in a registry or an index.
Obesity accelerates cardiovascular ageing
Open accessAbstract
A global obesity pandemic, coupled with an increasingly ageing population, is exacerbating the burden of cardiovascular disease. Indeed, clinical and experimental evidence underscores a potential connection between obesity and ageing in the pathogenesis of various cardiovascular disorders. This is further supported by the notion that weight reduction not only effectively reduces major cardiovascular events in elderly individuals but is also considered the gold standard for lifespan extension, in obese and non-obese model organisms. This review evaluates the intricate interplay between obesity and ageing from molecular mechanisms to whole organ function within the cardiovascular system. By comparatively analysing their characteristic features, shared molecular and cell biological signatures between obesity and ageing are unveiled, with the intent to shed light on how obesity accelerates cardiovascular ageing. This review also elaborates on how emerging metabolic interventions targeting obesity might protect from cardiovascular diseases largely through antagonizing key molecular mechanisms of the ageing process itself. In sum, this review aims to provide valuable insight into how understanding these interconnected processes could guide the development of novel and effective cardiovascular therapeutics for a growing aged population with a concerning obesity problem.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Obesity substantially increases the risk of diabetes, cardiovascular disease, fatty liver disease, and certain cancers, while imposing enormous societal and economic burdens.[2][3][4]”
From The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities (2026) · cites this paper as [3]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Obesity is associated with macrophage accumulation in adipose tissue
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319246 · Cited by 10,041
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“259,260 Indeed, in a Phase 3 trial, tirzepatide treatment of patients with obesity and HFpEF significantly lowered the risk of cardiovascular death and heart failure worsening.”
Obesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., & Eckel, R. H. (2006) · Circulation · doi:10.1161/circulationaha.106.171016 · Cited by 3,165
Cited by
Sorted by citations
Ganamurali, N., & Sabarathinam, S. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.70001 · Cited by 8
Metadata
- Authors
- Ruperez, C., Madeo, F., de Cabo, R., Kroemer, G., & Abdellatif, M.
- Affiliations
- Department of Cardiology, Medical University of Graz , Auenbruggerplatz 15, Graz 8036 ,
- University of Graz (AT)
- Translational Gerontology Branch, National Institute on Aging , Baltimore, MD ,
- Inserm (FR)
- Corresponding author
- Kroemer, Guido
- Abdellatif, Mahmoud
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2025-04-08
- Volume
- 46
- Issue
- 23
- Pages
- 2161-2185
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC12167665
- OpenAlex
- W4409261750
- Cited by
- 73
- References
- 295
- Citations by year
- 2026: 53 · 2025: 20
- FWCI
- 13.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Heart Journal (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nc)
- Funders
- Medical University of Graz
- BioTechMed-Graz
- Austrian Science Fund
- European Commission
- FWF
- ANR
- Agence National de la Recherche (ANR-22-CE14-0066, ANR-23-CE44-0030, ANR-23-R4HC-0006)
- Association pour la recherche sur le cancer
- Cancéropôle Ile-de-France
- Fondation pour la Recherche Médicale
- European Joint Programme on Rare Diseases
- European Research Council Advanced Investigator Award (101052444)
- European Union Horizon 2020 research and innovation programmes Oncobiome (825410)
- Prevalung (101095604)
- Neutrocure (861878)
- Hevolution Network on Senescence in Aging
- Institut National du Cancer
- Institut Universitaire de France
- Mark Foundation
- PAIR-Obésité INCa_1873
- LUCA-pi (ANR-21-RHUS-0017, ANR-23-RHUS-0010)
- Seerave Foundation
- SIRIC Cancer Research and Personalized Medicine
- Ministère des Solidarités et de la Santé
- INSERM
- University of Graz
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- obesity, cardiovascular aging, cardiovascular disease, weight loss, lifespan extension, metabolic intervention, cardiovascular therapeutics, older adults
- MeSH terms
- Aging, Animals, Cardiovascular Diseases, Humans, Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review